


THE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES?

Alexandru ENIU, MD, PhD
Chair, ESMO Global Policy Committee
Department of Breast Tumors
Cancer Institute Ion Chiricuță
Cluj-Napoca, Romania




Disparities in cancer outcomes (survival) across Europe

Figures 2: Age-standardised incidence (rates per 100,000 person-year) vs. age-standardised five-year relative survival (%) for cancers of breast (women), prostate, skin melanoma by European region. Period of diagnosis 2000-2007. Countries represented by dots.



Factors accounting for cancer outcomes disparities



ESMO Anti-Neoplastic Medicines Survey

Perception survey to **map access to cancer medicines**, including WHO Essential Medicines, reporting on:

■ Approval status (yes/no)

- Informative for new drugs

■ Reimbursement (yes/no)

- Highlight differences in cancer policies
- Residual (out of pocket) cost to patients
- Delays in access due to special authorization

■ Actual availability

- Drug shortage for old drugs
- Unavailability in the pharmacy (parallel export) for expensive drugs

■ Two steps: European Data and International Data

Coordinating & Collaborating Partners

■ Coordinating Organization

- ESMO

■ Collaborating Project Partners

1. World Health Organization (WHO), Geneva, Switzerland
2. Union for International Cancer Control (UICC), Geneva, Switzerland
3. Institute of Cancer Policy, Kings College, London, UK
4. European Society of Oncology Pharmacists

INTERNATIONAL SURVEY

- Breast Cancer(adjuvant)
- Breast Cancer (metastatic)
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Renal cell Cancer
- GIST
- Melanoma

Coordinating and Collaborating Partners

■ Collaborating Project Partners

- American Society of Clinical Oncology (ASCO)
- Chinese Society of Clinical Oncology (CSCO)
- Indian Society for Medical & Pediatric Oncology (ISMPO)
- Japanese Society of Medical Oncology (JSMO)
- Korean Association of Clinical Oncology (KACO)
- Myanmar Oncology Society (MOS)
- Medical Oncology Group of Australia Incorporated (MOGA)
- Medical Oncology Society of Peru (SPOM)
- Middle East Cancer Consortium (MECC)

Example of form :Metastatic Breast Cancer

BREAST CANCER (METASTATIC)

	Is it permitted to prescribe the medication for this indication?		Is the medicine reimbursed for this indication?		Does reimbursement require pre-authorization?		Does the pre-authorization process delay treatment by more than 4 weeks?		Cost of medication to patients (What proportion of the full retail price does the AVERAGE PATIENT have to pay?)					<u>Actual</u> availability when needed for most patients in your country (Can patients actually get the medication when it is prescribed?)					If the medication is not always available, what are the reasons for this (one or more)?				
	Yes	No	Yes	No	Yes	No	Yes	No	Free	<25% cost	25-50% cost	Discount <50%	Full cost	Always	Usually	Half the time	Occasionally	Never	No / unreliable supplier	No commercial motive *	Parallel export **	Manufacturing problems	Budget capitation ***
Albumin-bound paclitaxel	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anastrozole	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Bevacizumab	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Capecitabine	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Carboplatinum	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cisplatinum	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cyclophosphamide IV	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cyclophosphamide (tablets)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Denosumab	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Docetaxel	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Doxorubicin	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Epirubicin	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Eribulin	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Data reporters

- ESMO National representatives
- Known credible professionals nominated by coordinating and collaborating partners
- Minimum of 2 reporters for each country nominated
- Total 439 from 119 countries
 - 185 from 49 European countries,
 - 254 from 70 countries worldwide
- Respondents
 - 42 oncology pharmacists (22 countries)
 - 147 oncologists
 - 90 Academic cancer centers or hospitals

Response Rates

	Total Countries	Surveyed Countries	percent	Total Pop (bil)	Surveyed population	Percent
Sub Saharan Africa	51	9	18%	0.795	0.245	32%
North Africa	6	4	67%	0.161	0.155	96%
Mid East	16	9	56%	0.195	0.117	60%
Asia and Indian	29	13	49%	3.703	3.192	86%
Ocana	21	1	5%	0.033	0.02	61%
N America	5	2	40%	0.332	0.332	100%
Latin AM and Carrib	45	6	13%	0.562	0.423	75%
	173	44	25%	5.781	4.484	76%



WHO ESSENTIAL MEDICINES LIST 2015

Solid Tumors

- **UICC Task Force on EML:** UICC, Dana Farber Cancer Institute, ESMO, ASCO, SIOP, US NCI, NCCN International & others
- New drugs, tumor-specific indications



Cytotoxics	Cytotoxics	Cytotoxics	Hormones
bleomycin	docetaxel	irinotecan	anastrozole
calcium folinate	doxorubicin	methotrexate	bicalutamide
capecitabine	etoposide	oxaliplatin	dexamethasone
carboplatin	fluorouracil	paclitaxel	leuprorelin
cisplatin	filgrastim	rituximab	tamoxifen
cyclophosphamide	gemcitabine	trastuzumab	
dacarbazine	Ifosfamide+mesna	vinblastine	
dactinomycin	imatinib	vincristine	
		vinorelbine	

Adjuvant breast cancer: : formulary inclusion and availability : TAMOXIFEN



- Drug shortages affect several essential, old and inexpensive drugs (tamoxifen, doxorubicin, cisplatin, 5-FU, bleomycin...)
- Not an issue of resources!

Multi-use (WHO) Essential Medicines: Cost & availability




■ Free
 ■ <25% cost
 ■ 25-50% cost
 ■ Discount >50% and < 100%
 ■ Full cost
 ■ Not available
 ■ Missing data
 ■ European Data

Adjuvant breast cancer: TRASTUZUMAB formulary inclusion, cost, preapproval and delays

**Formulary
and cost
to patients**



Availability



**Preapproval
required**



**Delays >4
weeks**



High

Multi-use EML

**Upper
Middle**

**Low
Middle**

Low

COST AND AVAILABILITY															
Country	Bleo	CarboP	CisP	Cyclo (IV)	Cyclo (tab)	DTIC	Dox.	Epir.	Etop (IV)	5FU	Ifos.	MTX (IV)	MTX (tab)	VBL	VCR
Argentina	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Australia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Canada	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Chile	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Cyprus	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Israel	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Japan	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Korea, South	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Oman	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Qatar	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Saudi Arabia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Singapore	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
United Arab Emirates	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
USA	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Algeria	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Brazil	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
China	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Colombia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Iran	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost	<25% cost
Kazakhstan	Free	Free	Free	Free	Not available	Free	Free	Free	Free	Free	Free	Free	Not available	Free	Free
Lebanon	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Malaysia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Mexico	Free	Free	Free	Free	Not available	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Peru	Free	Free	Free	Free	Not available	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
South Africa	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Thailand	Free	Free	Free	Free	Free	Not available	Free	Not available	Free	Free	Free	Free	Free	Free	Free
Tunisia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Turkey	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Bangladesh	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Egypt	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Ghana	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
India	<25% cost	25-50% cost	25-50% cost	25-50% cost	25-50% cost	Full cost	25-50% cost	Full cost	Full cost	25-50% cost	Full cost	Full cost	Full cost	Full cost	Full cost
Kenya	Full cost	Full cost	Full cost	Full cost	Not available	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Morocco	Free	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Discount >50% and <100%	Not available	Discount >50% and <100%	Discount >50% and <100%
Pakistan	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Palestine	Free	Free	Free	Free	Not available	Free	Free	Not available	Free	Free	Free	Free	Free	Free	Free
Sudan	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Vietnam	Free	Free	Free	Free	Not available	Free	25-50% cost	Free	Free	Free	Free	Free	Not available	Free	Free
Zambia	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Afghanistan	Full cost	Full cost	Full cost	Full cost	Not available	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Burkina Faso	Free	Full cost	Full cost	Full cost	Not available	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Tanzania	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost
Uganda	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free	Free
Zimbabwe	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost	Full cost

Free
<25% cost
25-50% cost
Discount >50% and <100%
Full cost
Not available
Missing data



Field testing Breast Cancer

Medication	Trial	Setting	Primary outcome	PFS control	PFS gain	PFS HR	OS control	OS gain	OS HR	QoL	ESMO MCBS
Chemo +/- trastuzumab	HERA	(Neo)Adjuvant HER-2 positive tumors	DFS	2 y DFS 77.4%	8.4%	0.54 (0.43-0.67)					A
T-DM1 vs capecitabine + lapatinib	EMILIA	2 nd line metastatic after trastuzumab failure	PFS & OS	6.4 m	3.2 m	0.65 (0.55-0.77)	25 m	6.8 m	0.68 (0.55-0.85)	Later deterioration	5
Trastuzumab + chemo +/- pertuzumab	CLEOPATRA	1 st line metastatic	PFS	12.4 m	6 m	0.62 (0.52-0.84)	40.8 m	15.7 m	0.68 (0.56-0.84)	~	4
Lapatinib +/- trastuzumab	EGF 104900	3 rd line metastatic	PFS	2 m	1 m	0.73 (0.57-0.93)	9.5 m	4.5 m	0.74 (0.57-0.97)		4
Capecitabine +/- lapatinib	Geyer, 2006	2 nd line metastatic after trastuzumab failure	PFS	4.4 m	4 m	0.49 (0.34-0.71)			NS		3
Eribulin vs other chemo	EMBRACE	3 rd line metastatic after anthracycline & taxane	OS				10.6 m	2.5 m	0.81 (0.66-0.99)		2
Paclitaxel +/- bevacizumab	Miller, 2007	1 st line metastatic	PFS	5.9 m	5.8 m	0.6 (0.51-0.70)			NS	~	2
Exemestane +/- everolimus	BOLERO-2	Metastatic after failure aromatase inhibitor+PFS >6 m	PFS	4.1 m	6.5 m	0.43 (0.36-0.54)			NS	~	2

Example of using MCBS data: Breast cancer, Romania

Medication	Setting	Primary outcome	ESMO-MCBS
Chemotherapy +/- trastuzumab	(Neo)adjuvant HER-2 positive tumours	DFS	A
T-DM1 vs lapatinib + capecitabine	2nd line metastatic after trastuzumab failure	PFS and OS	5
Trastuzumab + chemotherapy +/- pertuzumab	1st line metastatic	PFS	4
Lapatinib +/- trastuzumab	3rd line metastatic	PFS	4
Capecitabine +/- lapatinib	2nd line metastatic after trastuzumab failure	PFS	3
Eribulin vs other chemotherapy	3rd line metastatic after anthracycline and taxane	OS	2
Paclitaxel +/- bevacizumab	1st line metastatic	PFS	2
Exemestane +/- everolimus	Metastatic after failure of aromatase inhibitor (with PFS > 6 mth)	PFS	2

Conclusions

- Disparities exist across Europe and the world in access to the WHO essential cancer medicines
- Drug shortages affect several “essential”, old and inexpensive drugs
 - THIS SHOULD BE UNACCEPTABLE !
- Many cheap generic medicines on the WHO EML are only available at full cost in many low-income countries
- No/unreliable distribution =major barrier
- The **ESMO Magnitude of Benefit Scale**, applied on the availability data (**ESMO Antineoplastic Medicines Survey**) can inform the process of prioritization access to medicines, when resources are limited

Special Acknowledgments

Project Leader:

European Society for Medical Oncology (ESMO)

Coordinating Partners:

- World Health Organization (WHO)
- Kings College London Institute of Cancer Policy
- European Society of Oncology Pharmacy (ESOP) and International Society of Oncology Pharmacy Practitioners (ISOPP)
- Union for International Cancer Control (UICC)

ESMO Logistics

Gracemarie Bricalli, Project Manager

Nicola Latino, Project Co Manager

Tanya Kenny, Project Coordinator

Sara Corbino, Survey Coordinator

Collaborating Partners:

- American Society of Clinical Oncology (ASCO)
- Chinese Society of Clinical Oncology (CSCO)
- Indian Society for Medical & Pediatric Oncology (ISMPO)
- Japanese Society of Medical Oncology (JSMO)
- Korean Association for Clinical Oncology (KACO)
- Myanmar Oncology Society (MOS)
- Medical Oncology Group of Australia Incorp. (MOGA)
- Medical Oncology Society of Peru (SPOM)
- Middle East Cancer Consortium (MECC)

Collaborators

- African Organisation for Research and Training in Cancer (AORTIC)
- Latinamerican & Caribbean Society of Medical Oncology (SLACOM)

104 individual reporters